Markers

Thematic Poster Session
Chairs: C. F. Donner (Borgomanero, Italy), F. Luppi (Spilamberto, Italy), G. Huchon (Paris, France)

Download all media

Roflumilast added to triple therapy in severe COPD patients with frequent exacerbations: Efficacy and tolerability M. Muñoz-Esquerre, M. Diez-Ferrer, C. Montón, X. Pomares, M. López-Sánchez, D. Huertas, F. Manresa, J. Dorca, S. Santos (L'Hospitalet de Llobregat, Sabadell, Spain)
COPD: Left ventricular dysfunction, systemic inflammation and endothelial dysfunction N. Egorova, N. Kuzubova, A. Gichkin, E. Surkova (Saint-Petersburg, Russian Federation)
The role of COPD in development of osteoporosis I. Zhila, N. Shaporova, O. Zhila, O. Galkina, E. Bogdanova (Saint Petersburg, Russian Federation)
Effect of tiotropium bromide on collagen-IV level: Results from 180-days study in subjects with moderate COPD M. Ostrovskyy, M. Kulynych-Miskiv, I. Savelikhina, O. Varunkiv (Ivano-Frankivsk, Ukraine)
Mortality risk prediction in COPD by a prognostic biomarker panel – Results of a derivation and validation cohort with a long term follow-up S. Daiana, A. Meyer, J. Rakic, L. Boeck, A. Scherr, M. Tamm (Basel, Switzerland)
Association between inhaled corticosteroid use in COPD and incidence or worsening of type2 diabetes S. Schembri, R. Flynn, A. Hapca, I. Mackenzie, T. MacDonald (Dundee, United Kingdom)
COPD-specific co-morbidity test (COTE) for predicting mortality in COPD – Results of an European, multicenter study D. Stolz, R. Louis, W. Boersma, B. Milenkovic, K. Kostikas, F. Blasi, J. Aerts, G. Rohde, A. Marin, L. Boeck, J. Rakic, A. Scherr, A. Torres, T. Welte, M. Tamm (Basel, Switzerland; Alkmaar, Breda, Maastricht, Netherlands; Belgrad, Republic Of Serbia; Thessaloniki, Greece; Milan, Italy; Liege, Belgium; Badalona, Barcelona, Spain; Hannover, Hennigsdorf, Germany)
A multimarker approach to identify atherosclerosis in COPD L. Vanfleteren, M. Spruit, M. Groenen, E. Rutten, P. Bruijnzeel, E. Wouters, F. Franssen (Horn, Maastricht, Netherlands; Mölndal, Sweden)
Comparison of quantitative PCR and quantitative culture for the detection of airway pathogenic bacteria in COPD R. Singh, S. Thurston, A. Mackay, B. Kowlessar, J. Allinson, S. Brill, G. Donaldson, J. Wedzicha (London, United Kingdom)
Increased heart rate modulation, sympathetic dominance and systemic inflammation in chronic obstructive pulmonary disease D. J. Dash, S. K. Chhabra, M. Gupta, S. Ramaswamy, V. Bansal, K. K. Deepak (Delhi, New Delhi, India)
Use of a standardized order set in the management of an acute exacerbation of COPD N. Rajwani, M. Bhutani (Edmonton, Canada)
Frequency and severity of exacerbations reflect COPD severity, but not COPD phenotype as determined by quantitative CT F. Bigazzi, A. Garcea, M. Vannini, E. Torricelli, V. Luzzi, M. Paoletti, S. Diciotti, G. Camiciottoli, M. Pistolesi (Florence, Bologna, Italy)
Comparison of indacaterol with tiotropium or once-daily dual long-acting bronchodilator therapy with roflumilast for severe COPD A. Sadigov, A. Agayeva, A. Farman (Baku, Azerbaijan)
Can red blood cell morphology be an indicator for COPD exacerbations? K. C. Tertemiz, A. Ozgen Alpaydin, S. Salman, A. H. Cimrin (Izmir, Turkey)
Cognitive dysfunction is greater in patients hospitalised with COPD exacerbations than with worsening heart failure M. Bajaj, A. Tappouni, M. Tumilty, J. Dodd, P. Jones, E. Baker (London, Bristol, United Kingdom)
The role of inflammatory biomarkers and health related quality of life questionnaires in distinction of exacerbation and stable chronic obstructive pulmonary diseases B. Er Dedekarginoglu, E. Kupeli, N. Bayraktar, E. Ogus, G. Ulubay (Ankara, Turkey)
Neutrophil CD 64 expression as a diagnostic marker of pneumonia in patients with acute COPD exacerbation E. Titova, M. W. Aune, K. Fonn, A. H. Henriksen, A. åsberg (Trondheim, Norway)
Metabolomic signature in COPD. Plasma and lung tissue comparison identify sphingolipids as potential biomakers V. Pinto-Plata, M. Divo, C. Owen, F. Polverino, M. Laucho, B. Celi (Boston, United States Of America)